Kiniksa now expects 2023 ARCALYST net product revenue of between $220 million and $230 million compared to prior guidance of between $200 million and $215 million. Kiniksa now expects that its cash and cash equivalents will fund its current operating plan into at least 2027.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KNSA:
- A New 52-Week High for Kiniksa Pharmaceuticals
- Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution
- KNSA Upcoming Earnings Report: What to Expect?
- Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023
- Kiniksa Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference